Stempoint Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Stempoint Capital’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-150,000	Closed	-$90K	–	105
2026 Q1	$90K	Buy	+150,000	New	+$3.26M	0.02%	75
2025 Q4	–	Sell	-100,000	Closed	-$55K	–	110
2025 Q3	$55K	Buy	+100,000	New	+$1.31M	0.01%	82
2025 Q1	–	Sell	-234,100	Closed	-$51K	–	79
2024 Q4	$51K	Buy	234,100 +4,100	+2%	+$70.2K	0.01%	54
2024 Q3	$382K	Buy	+230,000	New	+$4.75M	0.11%	51

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Stempoint Capital's SNDX Position: Q2 2026 in Review

Stempoint Capital sold out of Syndax Pharmaceuticals (SNDX) in Q2 2026, closing a stake of 1,215,743 shares — an estimated $28.4M sold.

Stempoint Capital first reported a position in SNDX in Q4 2023 and held it in 10 quarters. The position peaked at $38M in Q4 2024. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Stempoint Capital reported no remaining Syndax Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Stempoint Capital sold 1,215,743 Syndax Pharmaceuticals shares in Q2 2026, an estimated $28.4M.
Stempoint Capital first reported a position in Syndax Pharmaceuticals in Q4 2023 and held it in 10 quarters.
Stempoint Capital's Syndax Pharmaceuticals position peaked at $38M in Q4 2024.
243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.